Biopharmaceutical stocks are moving higher Monday morning. Well, at least, AKCA stock and IONS stock are. Here’s why.
AKCA Stock Skyrockets: New Licensing Agreement With Pfizer Inc.On Monday, October 7, Akcea Therapeutics (NASDAQ:AKCA), which is an affiliate of Ionis Pharmaceuticals (NASDAQ:IONS), announced that it has entered into a worldwide exclusive licensing agreement with Pfizer, Inc. (NYSE:PFE), a company applying science to create therapies for people in need of improved quality of life. The licensing agreement is for AKCEA-ANGPTL3-LRx, which, according to the press release, is an investigational antisense therapy. It is being developed to treat ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.